The autophilic anti-CD20 antibody DXL625 displays enhanced potency due to lipid raft-dependent induction of apoptosis

Anti-Cancer Drugs

Volumn 21, Issue 5, 2010, Pages 532-542

  Bingaman, Marc G ^a   Basu, Gargi D ^a   Golding, Tiana C ^a   Chong, Samuel K ^a   Lassen, Andrew J ^a   Kindt, Thomas J ^a   Lipinski, Christopher A ^b  

^a InNexus Biotechnology Inc   (Canada)

^b MAYO CLINIC   (United States)

Author keywords

Apoptosis; CD20 receptor; DXL625; Rituxan

Indexed keywords

CALCIUM; CASPASE; CD20 ANTIBODY; DXL 625; RITUXIMAB; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; APOPTOSIS; ARTICLE; B CELL LYMPHOMA; BINDING AFFINITY; CALCIUM CHELATION; CANCER IMMUNOTHERAPY; CHELATION; COMPLEMENT DEPENDENT CYTOTOXICITY; CONJUGATION; CONTROLLED STUDY; CROSS LINKING; CYTOTOXICITY; DRUG SYNTHESIS; EXTRACELLULAR CALCIUM; GROWTH INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; LIPID RAFT; PRIORITY JOURNAL; SURFACE PLASMON RESONANCE; TUMOR CELL;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; ANTINEOPLASTIC AGENTS; APOPTOSIS; CALCIUM; CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; MEMBRANE MICRODOMAINS;

EID: 77951294947     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e328337d485     Document Type: Article

References (50)

1. Von Mehren M, Adams GP, Weiner LM. Monoclonal antibody therapy for cancer. Annu Rev Med 2003; 54:343-369.
2. Campbell P, Marcus R. Monoclonal antibody therapy for lymphoma. Blood Rev 2003; 17:143-152.
3. Hale G. Therapeutic antibodies - delivering the promise? Adv Drug Deliv Rev 2006; 7:633-639.
4. Scallon BJ, Snyder LA, Anderson GM, Chen Q, Yan L, Weiner LM, et al. A review of antibody therapeutics and antibody-related technologies for oncology. J Immunother 2006; 29:351-364.
5. Fleischmann RM. Safety of biologic therapy in rheumatoid arthritis and other autoimmune diseases: focus on rituximab. Semin Arthritis Rheum 2009; 38:265-280.
6. Davis TA, Grillo-Ló pez AJ,White CA, McLaughlin P, Czuczman MS, Link BK, et al. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. J Clin Oncol 2000; 18:3135-3143.
7. Plosker GL, Figgitt DP. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Drugs 2003; 63:803-843.
8. Boye J, Elter T, Engert A. An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab. Ann Oncol 2003; 14:520-535.
9. Robak T. Novel monoclonal antibodies for the treatment of chronic lymphocytic leukemia. Curr Cancer Drug Targets 2008; 8:156-171. (Pubitemid 351347252)
10. Kim JJ, Thrasher AJ, Jones AM, Davies EG, Cale CM. Rituximab for the treatment of autoimmune cytopenias in children with immune deficiency. Br J Haematol 2007; 138:94-96.
11. Eisenbeis CF, Caligiuri MA, Byrd JC. Rituximab: converging mechanisms of action in non-Hodgkin's lymphoma? Clin Cancer Res 2003; 9:5810-5812.
12. Maloney DG, Smith B, Rose A. Rituximab: mechanism of action and resistance. Semin Oncol 2002; 29:2-9.
13. Smith MR. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene 2003; 22:7359-7368.
14. Cragg MS, Bayne MC, Illidge TM, Valerius T, Johnson PW, Glennie MJ. Apparent modulation of CD20 by rituximab: an alternative explanation. Blood 2004; 103:3989-3990.
15. Glennie MJ, French RR, Cragg MS, Taylor RP. Mechanisms of killing by anti-CD20 monoclonal antibodies. Mol Immunol 2007; 44:3823-3837.
16. Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med 2000; 6:443-446.
17. Di Gaetano N, Cittera E, Nota R, Vecchi A, Grieco V, Scanziani E, et al. Complement activation determines the therapeutic activity of rituximab in vivo. J Immunol 2003; 171:1581-1587.
18. Cragg MS, Glennie MJ. Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents. Blood 2004; 103:2738-2743.
19. Golay J, Manganini M, Facchinetti V, Gramigna R, Broady R, Borleri G, et al. Rituximab-mediated antibody-dependent cellular cytotoxicity against neoplastic B cells is stimulated strongly by interleukin-2. Haematologica 2003; 88:1002-1012.
20. Golay J, Cittera E, Di Gaetano N, Manganini M, Mosca M, Nebuloni M, et al. The role of complement in the therapeutic activity of rituximab in a murine B lymphoma model homing in lymph nodes. Haematologica 2006; 91:176-183.
21. Ghetie MA, Bright H, Vitetta ES. Homodimers but not monomers of Rituximab (chimeric anti-CD20) induce apopotosis in human B-lymphoma cells and synergize with a chemotherapeutic agent and an immunotoxin. Blood 2001; 97:1392-1398.
22. Pedersen IM, Buhl AM, Klausen P, Geilser CH, Jurlander J. The chimeric anti-CD20 antibody rituximab induces apoptosis in B-cell chronic lymphocytic leukemia cells through a p38 mitogen activated protein-kinasedependent mechanism. Blood 2002; 99:1314-1319.
23. Van der Kolk LE, Evers LM, Omene C, Lens SM, Lederman S, van Lier RA, et al. CD20-induced B cell death can bypass mitocondria and caspase activation. Leukemia 2002; 16:1735-1744.
24. Zhang N, Khawli LA, Hu P, Epstein AL. Generation of rituximab polymer may cause hyper-cross-linking-induced apoptosis in non-Hodgkin's lymphomas. Clin Cancer Res 2005; 11:5971-5980.
25. Cardarelli PM, Quinn M, Buckman D, Fang Y, Colchr D, King DJ, et al. Binding to CD20 by anti-B1 antibody or F(ab')(2) is sufficient for induction of apoptosis in B-cell lines. Cancer Immunol Immunother 2002; 51:15-24.
26. Unruh TL, Li H, Mutch CM, Shariat N, Grigoriou L, Sanyal R, et al. Cholesterol depletion inhibits src family kinase-dependent calcium mobilization and apoptosis induced by rituximab crosslinking. Immunology 2005; 16:223-232.
27. Janas E, Priest R, Wilde JE, White JH, Malhotra R. Rituxan (anti-CD20 antibody)-induced translocation of CD20 into lipid rafts is crucial for calcium influx and apoptosis. Clin Exp Immunol 2005; 139:439-446.
28. Stavenhagen JB, Gorlatov S, Tuaillon N, Rankin CT, Li H, Burke S, et al. Fc optimization of therapeutic antibodies enhance their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fcgamma receptors. Cancer Res 2007; 67:8882-8890.
29. Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 2002; 99:754-758.
30. Weng WK, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 2003; 21:3940-3947.
31. Dall'Ozoo S, Tartas S, Paintaud G, Cartron G, Colombat P, Bardos P, et al. Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship. Cancer Res 2004; 64:4464-4469.
32. Zhao Y, Kohler H. Enhancing tumor targeting and apoptosis using noncovalent antibody homodimers. J Immunother 2002; 25:396-404.
33. Zhao Y, Lou D, Burke J, Kohler H. Enhanced anti-B-cell tumor effects with anti-CD20 superantibody. J Immunother 2002; 25:57-62.
34. Kaveri SV, Kang CY, Kohler H. Natural mouse and human antibodies bind to a peptide derived from a germline VH chain. Evidence for evolutionary conserved self-binding locus. J Immunol 1990; 145:4207-4213.
35. Halpern R, Kaveri SV, Kohler H. Human anti-phosphorylcholine antibodies share idiotopes and are self-binding. J Clin Invest 1991; 88:476-482.
36. Teeling JL, French RR, Cragg MS, van den Brakel J, Pluyter M, Huang H, et al. Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood 2004; 104:1793-11780
37. Alas S, Emmanouilides C, Bonavida B. Inhibition of interleukin 10 by rituximab results in down-regulation of bcl-2 and sensitization of B-cell non-Hodgkin's lymphoma to apoptosis. Clin Cancer Res 2001; 7:709-723.
38. Jazirehi AR, XH G, De Vos S, Emmanouilides C, Bonavida B. Rituximab (anti-CD20) selectively modified Bcl-xL and apoptosis protease activating factor-1 (Apaf-1) expression and sensitizes human non-Hodgkin's lymphoma B cell lines to paclitaxel-induced apoptosis. Mol Cancer Ther 2003; 2:1183-1193.
39. Bubien JK, Zhou LJ, Bell PD, Frizzell RA, Tedder TF. Transfection of the CD20 cell surface molecule into ectopic cell types generates a Ca2+ conductance found constitutively in B lymphocytes. J Cell Biol 1993; 121:1121-1132.
40. Hofmeister JK, Cooney D, Coggeshall KM. Clustered CD20 induced apoptosis: src-family kinase, the proximal regulator of tyrosine phosphorylation, calcium influx, and caspase 3-dependent apoptosis. Blood Cells Mol Dis 2000; 26:133-143.
41. Byrd JC, Kitada S, Flinn IW, Aron JL, Pearson M, Lucas D, et al. The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction. Blood 2002; 99:1038-1043.
42. Deans JP, Li H, Polyak MJ. CD20-mediated apoptosis: signalling through lipid rafts. Immunology 2002; 107:176-182.
43. Daniels I, Abulayha AM, Thomson BJ, Haynes AP. Caspase-independent killing of Burkitt lymphoma cell lines by rituximab. Apoptosis 2006; 11:1013-1023.
44. Alas S, Bonavida B. Rituximab inactivates signal transducer and activation of transcription 3 (STAT3) activity in B-non-Hodgkin's lymphoma through inhibition of the interleukin 10 autocrine/paracrine loop and results in downregulation of Bcl-2 and sensitization to cytotoxic drugs. Cancer Res 2001; 61:5137-5144.
45. Bonavida B, Vega MI. Rituximab-mediated chemosensitization of AIDS and non-AIDS non-Hodgkin's lymphoma. Drug Resist Updat 2005; 8:27-41.
46. Bonavida B. Rituximab-induced inhibition of antiapoptotic cell survival pathways: implications in chemo/immunoresistance, rituximab unresponsiveness, prognostic, and therapeutic interventions. Oncogene 2007; 26:3629-3636.
47. Hussain SR, Cheney CM, Johnson AJ, Lin TS, Grever MR, Caligiuri MA, et al. Mcl-1 is a relevant therapeutic target in acute and chronic lymphoid malignancies: down-regulation enhances rituximab-mediated apoptosis and complement-mediated cytotoxicity. Clin Cancer Res 2007; 13:2144-2150.
48. Jazirehi AR, Vega MI, Chatterjee D, Goodglick L, Bonavida B. Inhibition of the Raft-MEK1/2-ERK1/2 signaling pathway, Bcl-xL down-regulation, and chemosensitization of non-Hodgkin's lymphoma B cells by Rituximab. Cancer Res 2004; 64:7117-7726.
49. Jazirehi AR, Bonavida B. Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention. Oncogene 2005; 24:2121-2143.
50. Suzuki E, Umezawa K, Bonavida B. Rituximab inhibits the constitutively activated PI3K-Akt pathway in B-NHL cell lines: involvement in chemosensitization to drug-induced apoptosis. Oncogene 2007; 26:6184-6193.